Safety and Efficacy of Everolimus Rescue Treatment After Pediatric Living Donor Liver Transplantation

Ueno, Takehisa; Kodama, Tasuku; Noguchi, Yuki; Deguchi, Koichi; Nomura, Motonari; Saka, Ryuta; Watanabe, Miho; Tazuke, Yuko; Bessho, Kazuhiko; Okuyama, Hiroomi

doi:https://doi.org/10.1016/j.transproceed.2020.01.159

Safety and Efficacy of Everolimus Rescue Treatment After Pediatric Living Donor Liver Transplantation

Ueno, Takehisa; Kodama, Tasuku; Noguchi, Yuki et al.

Transplantation Proceedings, 2020, 52(6), 1829-1832

アクセス数:102件（2025-05-24 05:46 集計）

固定URL: https://hdl.handle.net/11094/96477

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
TransplantProc_52_6_1829	pdf	なし	185 KB	16	2024.07.01
TransplantProc_52_6_1829_figure	pdf	なし	120 KB	17	2024.07.01

Creative Commons : 表示 - 非営利 - 改変禁止

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	Safety and Efficacy of Everolimus Rescue Treatment After Pediatric Living Donor Liver Transplantation
著者	NRID 1000010456957 1000010456957 ORCID 0000-0002-4639-8814 0000-0002-4639-8814 researchmap permalink ueno-pedsurg ueno-pedsurg Scopus Author ID 21743992300 21743992300 著者名 Ueno, Takehisa
	NRID 1000060771045 1000060771045 著者名 Kodama, Tasuku
	NRID 1000030771042 1000030771042 著者名 Noguchi, Yuki
	NRID 1000000747082 1000000747082 researchmap permalink deguchi_koichi deguchi_koichi Scopus Author ID 57139781700 57139781700 著者名 Deguchi, Koichi
	NRID 1000040546909 1000040546909 researchmap permalink moto_pedsurg moto_pedsurg Scopus Author ID 35208741700 35208741700 ORCID 0009-0004-0959-7461 0009-0004-0959-7461 著者名 Nomura, Motonari
	NRID 1000000459190 1000000459190 ORCID 0000-0001-8960-8618 0000-0001-8960-8618 researchmap permalink sakaryuta sakaryuta 著者名 Saka, Ryuta
	NRID 1000040791728 1000040791728 researchmap permalink miho miho Scopus Author ID 56282966800 56282966800 ORCID 0000-0001-6691-0611 0000-0001-6691-0611 著者名 Watanabe, Miho
	NRID 1000010397698 1000010397698 researchmap permalink yukotazuke-osaka yukotazuke-osaka Scopus Author ID 7006109798 7006109798 ORCID 0000-0002-8335-0414 0000-0002-8335-0414 著者名 Tazuke, Yuko
	NRID 1000080423169 1000080423169 researchmap permalink KazuBe KazuBe 著者名 Bessho, Kazuhiko
	NRID 1000030252670 1000030252670 researchmap permalink okuyamahiroomi okuyamahiroomi Scopus Author ID 35496082300 35496082300 ORCID 0000-0002-1347-282X 0000-0002-1347-282X 著者名 Okuyama, Hiroomi
内容	Ueno T., Kodama T., Noguchi Y., et al. Safety and Efficacy of Everolimus Rescue Treatment After Pediatric Living Donor Liver Transplantation. Transplantation Proceedings 52, 1829 (2020); https://doi.org/10.1016/j.transproceed.2020.01.159.
抄録	Purpose: Everolimus (EVR) is a derivative of sirolimus with a similar mechanism of action. The safety and efficacy of EVR after pediatric living donor liver transplantation (LDLT) are currently unknown. The purpose of this study was to examine the safety and efficacy of EVR as rescue therapy after pediatric LDLT. Methods: This study included patients younger than 19 years of age who received EVR after LDLT at our institution. EVR was administered as rescue treatment in addition to tacrolimus. In 21 patients, EVR dose, trough level, outcomes, and adverse effects were assessed. Results: Original diseases of patients consisted of biliary atresia (n = 11), Alagille syndrome (n = 3), fulminant hepatitis (n = 3), hepatoblastoma (n = 2), and other (n = 2). Mean age at transplant was 2.0 years (range 0.6-6.2 years). Mean age at initial EVR administration was 8.0 years (range 0.9-18.9 years). Indications for EVR use were graft fibrosis (n = 8), refractory acute cellular rejection (n = 5), renal sparing (n = 4), hepatoblastoma (n = 2), and chronic rejection (CR) (n = 2). Mean duration of administration was 17.1 months (range 2.1-60.4 months). Mean dose was 0.5 mg/m2 twice daily. Mean EVR trough level was 2.5 ng/mL (range 1.5-5.0 ng/mL). Liver function improved and fibrosis did not progress in all patients with CR. However, 14 patients (67%) experienced adverse effects that required EVR dose reduction or discontinuation. Conclusion: EVR is tolerable for pediatric patients after LDLT with dose adjustment. EVR had a certain effect to relieve progression on CR. Further follow-up is required.
出版者	Elsevier Inc.
収録物名	Transplantation Proceedings
巻(号)	52(6)
ページ	1829-1832
刊行年月	2020-07-01
言語	英語
ハンドルURL	https://hdl.handle.net/11094/96477
PISSN	00411345
eISSN	18732623
関連情報 (isVersionOf)	DOI (出版社版) https://doi.org/10.1016/j.transproceed.2020.01.159
アクセス権	open access
権利情報	© 2020. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/
出版タイプ	Accepted Manuscript
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCTERMS.bibliographicCitation	Transplantation Proceedings. 2020, 52(6), p. 1829-1832
DC.title	Safety and Efficacy of Everolimus Rescue Treatment After Pediatric Living Donor Liver Transplantation
DC.creator	Ueno, Takehisa
	Kodama, Tasuku
	Noguchi, Yuki
	Deguchi, Koichi
	Nomura, Motonari
	Saka, Ryuta
	Watanabe, Miho
	Tazuke, Yuko
	Bessho, Kazuhiko
	Okuyama, Hiroomi
DC.publisher	Elsevier Inc.
DC.language' scheme='DCTERMS.RFC1766	英語
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2020-07-01
DC.identifier	https://doi.org/10.1016/j.transproceed.2020.01.159
DC.description	Ueno T., Kodama T., Noguchi Y., et al. Safety and Efficacy of Everolimus Rescue Treatment After Pediatric Living Donor Liver Transplantation. Transplantation Proceedings 52, 1829 (2020); https://doi.org/10.1016/j.transproceed.2020.01.159.
DCTERMS.abstract	Purpose: Everolimus (EVR) is a derivative of sirolimus with a similar mechanism of action. The safety and efficacy of EVR after pediatric living donor liver transplantation (LDLT) are currently unknown. The purpose of this study was to examine the safety and efficacy of EVR as rescue therapy after pediatric LDLT. Methods: This study included patients younger than 19 years of age who received EVR after LDLT at our institution. EVR was administered as rescue treatment in addition to tacrolimus. In 21 patients, EVR dose, trough level, outcomes, and adverse effects were assessed. Results: Original diseases of patients consisted of biliary atresia (n = 11), Alagille syndrome (n = 3), fulminant hepatitis (n = 3), hepatoblastoma (n = 2), and other (n = 2). Mean age at transplant was 2.0 years (range 0.6-6.2 years). Mean age at initial EVR administration was 8.0 years (range 0.9-18.9 years). Indications for EVR use were graft fibrosis (n = 8), refractory acute cellular rejection (n = 5), renal sparing (n = 4), hepatoblastoma (n = 2), and chronic rejection (CR) (n = 2). Mean duration of administration was 17.1 months (range 2.1-60.4 months). Mean dose was 0.5 mg/m2 twice daily. Mean EVR trough level was 2.5 ng/mL (range 1.5-5.0 ng/mL). Liver function improved and fibrosis did not progress in all patients with CR. However, 14 patients (67%) experienced adverse effects that required EVR dose reduction or discontinuation. Conclusion: EVR is tolerable for pediatric patients after LDLT with dose adjustment. EVR had a certain effect to relieve progression on CR. Further follow-up is required.
DC.rights	© 2020. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/
DC.format	96477
citation_title	Safety and Efficacy of Everolimus Rescue Treatment After Pediatric Living Donor Liver Transplantation
citation_author	Ueno, Takehisa
	Kodama, Tasuku
	Noguchi, Yuki
	Deguchi, Koichi
	Nomura, Motonari
	Saka, Ryuta
	Watanabe, Miho
	Tazuke, Yuko
	Bessho, Kazuhiko
	Okuyama, Hiroomi
citation_publisher	Elsevier Inc.
citation_language	英語
citation_date	2020-07-01
citation_journal_title	Transplantation Proceedings
citation_volume	52
citation_issue	6
citation_firstpage	1829
citation_lastpage	1832
citation_doi	https://doi.org/10.1016/j.transproceed.2020.01.159
citation_public_url	https://hdl.handle.net/11094/96477

Safety and Efficacy of Everolimus Rescue Treatment After Pediatric Living Donor Liver Transplantation

閲覧可能ファイル

論文情報

論文詳細を表示